Refreshing results…
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Download from aacrjournals.orgARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Download from www.nature.comMissing publications? Search for publications with a matching author name.